Compounds > valnemulin
Page last updated: 2024-11-08

valnemulin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

valnemulin: a pleuromutilin derivative [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID443605
CHEBI ID29705
MeSH IDM0302264
PubMed CID9850878
CHEMBL ID1688852
SCHEMBL ID216709
MeSH IDM0302264

Synonyms (33)

Synonym
C12066 ,
valnemulin
D08665
valnemulin (inn)
AC1L9EWK ,
AKOS015907964 ,
CHEBI:29705
[(1s,2r,3s,4s,6r,7r,8r)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[1-[(2-amino-3-methylbutanoyl)amino]-2-methylpropan-2-yl]sulfanylacetate
(hydroxy-tetramethyl-oxo-vinyl-[?]yl) 2-[2-[[(2r)-2-amino-3-methyl-butanoyl]amino]-1,1-dimethyl-ethyl]sulfanylacetate
101312-92-9
NCGC00167968-01
CHEMBL1688852
valnemulin [inn:ban]
2ahc415bqg ,
unii-2ahc415bqg
((2-((r)-2-amino-3-methylbutyramido)-1,1-dimethylethyl)thio)acetic acid, 8-ester with (3as,4r,5s,6s,8r,9r,9ar,10r)-octahydro-5,8-dihydroxy-4,6,9,10-tetramethyl-6-vinyl-3a,9-propano-3ah-cyclopentacycloocten-1(4h)-one
dtxsid2046751 ,
dtxcid0026751
tox21_112596
cas-101312-92-9
SCHEMBL216709
valnemulin [mart.]
valnemulin [mi]
valnemulin [ema epar veterinary]
AB01566922_01
[(1s,2r,3s,4s,6r,7r,8r,14r)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[1-[[(2r)-2-amino-3-methylbutanoyl]amino]-2-methylpropan-2-yl]sulfanylacetate
Q7912519
acetic acid,[[2-[[(2r)-2-amino-3-methyl-1-oxobutyl]amino]-1,1-dimethylethyl]thio]-,(3as,4r,5s,6s,8r,9r,9ar,10r)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-ylester
valnemulinum
valnemuline
valnemulin (ema epar veterinary)
valnemulina
valnemulin (mart.)

Research Excerpts

Overview

Valnemulin (VML) is a semi-synthetic pleuromutilin derivative widely used to treat animal bacterial diseases.

ExcerptReferenceRelevance
"Valnemulin (VML) is a semi-synthetic pleuromutilin derivative widely used to treat animal bacterial diseases. "( UPLC-MS/MS Method for Simultaneous Determination of Valnemulin and Its Metabolites in Crucian Carp: In Vivo Metabolism and Tissue Distribution Analyses.
Liu, W; Wang, Q; Yang, Q; Zhang, X; Zhong, Y, 2023)		2.6
"Valnemulin is a pleuromutilin antibiotic used in clinics for the treatment of various infections. "( Valnemulin downregulates nitric oxide, prostaglandin E2, and cytokine production via inhibition of NF-kappaB and MAPK activity.
Deng, X; Feng, H; Li, H; Song, Y; Xiong, H; Yu, L; Zhang, L; Zhang, X, 2009)		3.24
"Valnemulin should prove to be a useful addition to the antimicrobials in the control of MG infection in chickens."( In vitro and in vivo comparisons of valnemulin, tiamulin, tylosin, enrofloxacin, and lincomycin/spectinomycin against Mycoplasma gallisepticum.
Burch, DG; Forrester, CA; Jordan, FT; Ripley, PH, )		1.13

Effects

ExcerptReferenceRelevance
"Valnemulin has low water-solubility, a short half-life period, low bioavailability, and instability."( Synthesis, characterization and in vitro release performance of the pegylated valnemulin prodrug.
Dong, X; Niu, Z; Shu, X; Wang, Y; Xu, S; Zhang, Y; Zhao, S, 2018)		1.43

Pharmacokinetics

A flow-limited, physiologically based pharmacokinetic (PBPK) model for predicting the plasma and tissue concentrations of valnemulin after a single oral administration to rats was developed. Data were extrapolated to pigs so as to predict withdrawal interval in edible tissues.

ExcerptReferenceRelevance
"A flow-limited, physiologically based pharmacokinetic (PBPK) model for predicting the plasma and tissue concentrations of valnemulin after a single oral administration to rats was developed, and then the data were extrapolated to pigs so as to predict withdrawal interval in edible tissues."( A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs.
Liu, YH; Luo, XY; Wang, R; Yuan, LG; Zhu, LX, 2011)		0.83
" Pharmacokinetic characterization was performed by non-compartmental analysis using WinNonlin program."( Pharmacokinetics and bioavailability of valnemulin in broiler chickens.
Fang, BH; He, LM; Liu, YH; Luo, XY; Wang, R; Yu, JJ; Yuan, LG; Zhang, CY; Zhu, LX, 2011)		0.64
" A pharmacokinetic study of valnemulin was conducted in healthy Muscovy ducks after intravenous (IV), intramuscular (IM) and oral administrations at a dose rate of 15 mg/kg body weight."( Pharmacokinetics and bioavailability of valnemulin in Muscovy ducks (Cairina moschata).
He, L; Liu, Y; Luo, X; Sun, J; Wang, R; Yuan, L; Zhu, L, 2012)		0.94
"This study was carried out in 121 pigs to develop a population pharmacokinetic (PPK) model by oral (p."( Population pharmacokinetics of valnemulin in swine.
Deng, H; Guo, JP; Liu, YH; Liu, ZC; Yu, JJ; Zhang, CY; Zhang, Z; Zhao, DH, 2014)		0.69
" administration, the mean values of Cmax , Tmax , AUClast , MRT, CLβ /F, Vz /F, and t1⁄2β , were 27."( Mycoplasma gallisepticum and Escherichia coli mixed infection model in broiler chickens for studying valnemulin pharmacokinetics.
Deng, H; Liu, YH; Ma, J; Shi, W; Xiao, X; Yang, X; Zhang, S; Zhao, DH, 2014)		0.62
"To estimate the valnemulin pharmacokinetic profile in a swine population and to assess a dosage regimen for increasing the likelihood of optimization."( Dosage assessment of valnemulin in pigs based on population pharmacokinetic and Monte Carlo simulation.
Liu, YH; Luo, XY; Sun, J; Tang, YZ; Wang, R; Yuan, LG; Zhang, YX; Zhang, Z; Zhu, LX, 2015)		1.08
"The pharmacokinetic (PK) and ex vivo pharmacodynamic (PD) of valnemulin against Clostridium perfringens were investigated in plasma, the small intestinal and caecal contents of rabbits following intravenous (IV) or oral administration at 3 mg/kg bodyweight (BW)."( Ex vivo pharmacokinetic/pharmacodynamic relationship of valnemulin against Clostridium perfringens in plasma, the small intestinal and caecal contents of rabbits.
Li, X; Liao, XP; Liu, YH; Sun, J; Tao, MT; Yu, Y; Zhou, WJ; Zhou, YF, 2016)		0.92

Bioavailability

The objective of this study was to investigate the pharmacokinetics and bioavailability of valnemulin in broiler chickens after intravenous (i.e., intramuscular) and oral administration. The prepared granules improved the oral bioavailability by 3.

ExcerptReferenceRelevance
"The objective of this study was to investigate the pharmacokinetics and bioavailability of valnemulin in broiler chickens after intravenous (i."( Pharmacokinetics and bioavailability of valnemulin in broiler chickens.
Fang, BH; He, LM; Liu, YH; Luo, XY; Wang, R; Yu, JJ; Yuan, LG; Zhang, CY; Zhu, LX, 2011)		0.86
" Following intramuscular and oral administration, valnemulin was rapidly absorbed; the C(max) was 0·44 ± 0·13 and 0·12 ± 0·02 µg/ml (achieved at 0·28 and 1·80 h), the t(1/2Ke) was 3·17 ± 3·83 and 4·83 ± 1·81 h, and the absolute bioavailability (F) was 72% and 37%, respectively."( Pharmacokinetics and bioavailability of valnemulin in Muscovy ducks (Cairina moschata).
He, L; Liu, Y; Luo, X; Sun, J; Wang, R; Yuan, L; Zhu, L, 2012)		0.9
" Pharmacokinetic studies indicate that 1 has an oral bioavailability with an average F-value of 27."( An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
Eslamimehr, S; Franzblau, SG; Kong, Y; Kurosu, M; Lemieux, MR; Mitachi, K; Park, F; Pressly, JD; Siricilla, S; Wang, Y; Yang, D, 2018)		0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51

Dosage Studied

Varnemulin exhibited rapid, time-dependent killing feature. Ex-vivo dose-response profile was closely fitted to sigmoid Emax model. The result suggests a longer dosing interval while formulating a daily administration dosage.

ExcerptRelevanceReference
" Based on liver tissue residue profiles, the pig model estimated a withdrawal interval of 10 h under a multiple oral dosing schedule (5."( A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs.
Liu, YH; Luo, XY; Wang, R; Yuan, LG; Zhu, LX, 2011)		0.62
" aureus, supporting a longer dosing interval while formulating a daily administration dosage."( Postantibiotic effect and postantibiotic sub-minimum inhibitory concentration effect of valnemulin against Staphylococcus aureus isolates from swine and chickens.
Deng, H; Liu, YH; Shi, W; Yu, Y; Zhao, DH; Zhou, YF, 2014)		0.62
" The result suggests a longer dosing interval while formulating a daily administration dosage, and it may play a valuable role of valnemulin in treating Staph."( Postantibiotic effect and postantibiotic sub-minimum inhibitory concentration effect of valnemulin against Staphylococcus aureus isolates from swine and chickens.
Deng, H; Liu, YH; Shi, W; Yu, Y; Zhao, DH; Zhou, YF, 2014)		0.83
"To estimate the valnemulin pharmacokinetic profile in a swine population and to assess a dosage regimen for increasing the likelihood of optimization."( Dosage assessment of valnemulin in pigs based on population pharmacokinetic and Monte Carlo simulation.
Liu, YH; Luo, XY; Sun, J; Tang, YZ; Wang, R; Yuan, LG; Zhang, YX; Zhang, Z; Zhu, LX, 2015)		1.08
" A dosage regimen of 12."( Ex vivo pharmacokinetic and pharmacodynamic analysis of valnemulin against Mycoplasma gallisepticum S6 in Mycoplasma gallisepticum and Escherichia coli co-infected chickens.
Chen, Y; Liu, YH; Sun, J; Xiao, X; Zhao, DH; Zou, M, 2015)		0.66
" Valnemulin exhibited rapid, time-dependent killing feature, and the ex vivo dose-response profile was closely fitted to sigmoid Emax model (r(2) = 0."( Ex vivo pharmacokinetic/pharmacodynamic relationship of valnemulin against Clostridium perfringens in plasma, the small intestinal and caecal contents of rabbits.
Li, X; Liao, XP; Liu, YH; Sun, J; Tao, MT; Yu, Y; Zhou, WJ; Zhou, YF, 2016)		1.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
carbotricyclic compoundA carbopolyclic compound comprising of three carbocyclic rings.
carboxylic esterAn ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
cyclic ketone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.25160.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency26.33060.000221.22318,912.5098AID743035; AID743042; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency11.98560.000214.376460.0339AID720691
pregnane X nuclear receptorHomo sapiens (human)Potency8.91250.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.80290.000229.305416,493.5996AID743079; AID743080; AID743091
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency21.13170.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency7.07950.10009.191631.6228AID1346983
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency7.07950.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency10.71460.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (137)

Assay IDTitleYearJournalArticle
AID1067009Antimicrobial activity against methicillin-resistant Escherichia coli AS19 after 20 hrs by two-fold broth dilution assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID1400039Bactericidal activity against Staphylococcus aureus ATCC 25923 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID684097Antibacterial activity against Escherichia coli AS19 after 24 hrs by microtitre plate reader2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
A click chemistry approach to pleuromutilin derivatives, part 2: conjugates with acyclic nucleosides and their ribosomal binding and antibacterial activity.
AID1428684Antibacterial activity against Staphylococcus aureus ATCC 29213 after overnight incubation by broth dilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127Design, synthesis and antibacterial evaluation of novel pleuromutilin derivatives possessing piperazine linker.
AID1400048Antibacterial activity against Enterococcus faecalis ATCC 19433 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1067015Binding affinity to Escherichia coli MRE600 23S rRNA assessed as protection of A2058 at 25 uM by footprinting assay relative to control in presence of DMS2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID1400046Antibacterial activity against Enterococcus faecalis ATCC 349 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1701637Antibacterial activity against methicilin-resistant Staphylococcus aureus 4828 incubated for 20 to 24 hrs by microbroth dilution assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID1067013Binding affinity to Escherichia coli MRE600 23S rRNA assessed as protection of A2059 at 25 uM by footprinting assay relative to control in presence of DMS2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID585171Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA C2055A, U2504G mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1364636Solubility of the compound in water at 10 mg after 24 hrs by HPLC based shake flask method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID1638647Fraction unbound in mouse plasma at 1 uM2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.
AID1364626Half life in Sprague-Dawley rat liver microsomes at 500 ng/ml by LC/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID1400059Antibacterial activity against Streptococcus salivarius ATCC 6301 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400045Bactericidal activity against Staphylococcus aureus BAA 44 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1364621Potentiation of doxycycline-induced antimicrobial activity against Acinetobacter baumannii ATCC 19606 at 0.78 ug/ml in presence of 0.025 ug/ml doxycycline by microdilution broth checkerboard method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID1154695Oral bioavailability in Sprague-Dawley rat2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID1428683Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after overnight incubation by broth dilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127Design, synthesis and antibacterial evaluation of novel pleuromutilin derivatives possessing piperazine linker.
AID744248Antibacterial activity against methicillin-resistant Staphylococcus epidermidis after 48 hrs by agar dilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID1400021Antibacterial activity against Mycobacterium smegmatis2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400038Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1364570Bactericidal activity against Acinetobacter baumannii ATCC 19606 after 48 hrs by resazurin dye based microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID684094Binding affinity to Escherichia coli 23S rRNA U2506 assessed as degree of protection against CMCT at 50 uM by Chemical footprinting analysis relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
A click chemistry approach to pleuromutilin derivatives, part 2: conjugates with acyclic nucleosides and their ribosomal binding and antibacterial activity.
AID744241Antibacterial activity against methicillin-resistant Staphylococcus epidermidis at 160 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID744236Antibacterial activity against Escherichia coli at 80 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID744245Antibacterial activity against methicillin-resistant Staphylococcus aureus at 320 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID1638648Apparent permeability of the compound in MDCK-MDR1 cells2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.
AID1400052Bactericidal activity against Streptococcus pneumoniae ATCC 6301 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID585172Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA C2055A mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID560248Antibacterial activity against Staphylococcus aureus RN4220 harboring aadD, tet(L), dfrK and vga(C) gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID585157Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA A2058G mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400050Bactericidal activity against Clostridium difficile ATCC 700057 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400049Bactericidal activity against Enterococcus faecalis ATCC 19433 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1067018Binding affinity to Escherichia coli MRE600 23S rRNA assessed as protection of U2506 at 5 uM by footprinting assay relative to control in presence of CMCT2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID1701651Cytotoxicity against human PC3 cells assessed as decrease in ATP level at 100 ug/ml incubated for 3 hrs by Cell-titer Glo assay relative to control2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID1400025Selectivity ratio of MIC for antibacterial activity against non-replicating Mycobacterium tuberculosis H37Rv harboring pFCA-luxAB to MIC100 for antibacterial activity against replicating Mycobacterium tuberculosis H37Rv2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID560250Antibacterial activity against Staphylococcus aureus RN4220 harboring aadD and tet(L) gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID1364625Potentiation of doxycycline-induced antimicrobial activity against Acinetobacter baumannii ATCC 19606 at 1.56 ug/ml in presence of 0.05 ug/ml doxycycline by microdilution broth checkerboard method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID585165Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA C2612A mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1701633Antibacterial activity against methicilin-resistant Staphylococcus aureus USA300 FPR3757 incubated for 20 to 24 hrs by microbroth dilution assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID744247Antibacterial activity against Escherichia coli after 48 hrs by agar dilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID1701640Cytotoxicity against differentiated human Caco2 cells assessed as increase in ATP level at 100 ug/ml incubated for 3 hrs by Cell-titer Glo assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID1400036Bactericidal activity against Mycobacterium smegmatis ATCC 607 incubated for 48 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID684095Binding affinity to Escherichia coli 23S rRNA U2585 assessed as degree of protection against CMCT at 5 uM by Chemical footprinting analysis relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
A click chemistry approach to pleuromutilin derivatives, part 2: conjugates with acyclic nucleosides and their ribosomal binding and antibacterial activity.
AID585159Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA A2453U mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400058Bactericidal activity against Escherichia coli ATCC 10798 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID509631Antimicrobial activity against Staphylococcus aureus RN4220 transformant carrying plasmid pKKS25 and expressing erm(T), dfrK and tet(L) genes by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID560247Antibacterial activity against Staphylococcus aureus RN4220 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID1701638Antibacterial activity against methicilin-resistant Staphylococcus epidermis 933010 incubated for 20 to 24 hrs by microbroth dilution assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID744235Antibacterial activity against Streptococcus agalactiae at 160 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID1701635Antibacterial activity against methicilin-resistant Staphylococcus aureus 55508 incubated for 20 to 24 hrs by microbroth dilution assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID684098Antibacterial activity against Listeria innocua after 24 hrs by microtitre plate reader2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
A click chemistry approach to pleuromutilin derivatives, part 2: conjugates with acyclic nucleosides and their ribosomal binding and antibacterial activity.
AID1867949Antibacterial activity against Mycoplasma pneumoniae assessed as inhibition of bacterial growth2022European journal of medicinal chemistry, Jul-05, Volume: 237Design, synthesis and antibacterial activity of novel pleuromutilin derivatives with thieno[2,3-d]pyrimidine substitution.
AID744244Antibacterial activity against methicillin-resistant Staphylococcus aureus at 160 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID1400037Bactericidal activity against Staphylococcus aureus incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400040Antibacterial activity against Staphylococcus aureus BAA 2094 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1154694Oral bioavailability in chicken2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID509630Antimicrobial activity against Staphylococcus aureus RN4220 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID684099Antibacterial activity against Bacillus subtilis 168 after 12 hrs by microtitre plate reader2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
A click chemistry approach to pleuromutilin derivatives, part 2: conjugates with acyclic nucleosides and their ribosomal binding and antibacterial activity.
AID744249Antibacterial activity against methicillin-resistant Staphylococcus aureus after 48 hrs by agar dilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID585158Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA G2032C mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1638645Intrinsic clearance in mouse liver S9 fraction2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.
AID1364567Growth inhibition of Acinetobacter baumannii ATCC 19606 after 48 hrs by resazurin dye based microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID1701649Cytotoxicity against human Caco2 cells assessed as cell viability at 100 ug/ml incubated for 3 hrs by MTT assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID1400047Bactericidal activity against Enterococcus faecalis ATCC 349 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID684264Antibacterial activity against Brachyspira pilosicoli2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Novel pleuromutilin derivatives as antibacterial agents: synthesis, biological evaluation and molecular docking studies.
AID1067012Binding affinity to Escherichia coli MRE600 23S rRNA assessed as protection of A2062 at 25 uM by footprinting assay relative to control in presence of DMS2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID1638644Antimicrobial activity against Wolbachia wMel infected in Drosophila melanogaster LDW1 cells after 6 days by DAPI-based fluorescence in-situ hybridization assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.
AID585170Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA U2504G mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400057Antibacterial activity against Escherichia coli ATCC 10798 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID684096Binding affinity to Escherichia coli 23S rRNA U2585 assessed as degree of protection against CMCT at 50 uM by Chemical footprinting analysis relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
A click chemistry approach to pleuromutilin derivatives, part 2: conjugates with acyclic nucleosides and their ribosomal binding and antibacterial activity.
AID585166Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA C2499A2 mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400033Half life in Sprague-Dawley rat liver microsomes at 500 ng/ml preincubated for 5 mins followed by NADPH addition by C-MS/MS analysis2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1364627Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID560249Antibacterial activity against Staphylococcus aureus RN4220 harboring tet(L), dfrK gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID585174Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA A2572U1 mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400026Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1701643Cytotoxicity against undifferentiated human Caco2 cells assessed as ATP level at 100 ug/ml incubated for 3 hrs by Cell-titer Glo assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID585168Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA G2032A mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400042Antibacterial activity against Staphylococcus aureus BAA 1683 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400061Antibacterial activity against Bacillus subtilis ATCC 6051 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400024Antibacterial activity against non-replicating Mycobacterium tuberculosis H37Rv harboring pFCA-luxAB preincubated for 10 days under anaerobic condition followed by incubation under ambient gaseous condition for 28 hrs by LORA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1067017Binding affinity to Escherichia coli MRE600 23S rRNA assessed as protection of U2506 at 50 uM by footprinting assay relative to control in presence of CMCT2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID1400051Antibacterial activity against Streptococcus pneumoniae ATCC 6301 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400041Bactericidal activity against Staphylococcus aureus BAA 2094 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID744246Antibacterial activity against Streptococcus agalactiae after 48 hrs by agar dilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID585169Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA G2032A, U2504G mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1067014Binding affinity to Escherichia coli MRE600 23S rRNA assessed as protection of U2585 at 50 uM by footprinting assay relative to control in presence of CMCT2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID744234Antibacterial activity against Streptococcus agalactiae at 80 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID744242Antibacterial activity against methicillin-resistant Staphylococcus epidermidis at 320 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID1400035Antibacterial activity against Mycobacterium smegmatis ATCC 607 incubated for 48 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1701636Antibacterial activity against methicilin-resistant Staphylococcus aureus 52518 incubated for 20 to 24 hrs by microbroth dilution assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID1400044Antibacterial activity against Staphylococcus aureus BAA 44 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID585160Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA C2499U mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID584971Antibacterial activity against Mycobacterium smegmatis SZ558 after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID744243Antibacterial activity against methicillin-resistant Staphylococcus aureus at 80 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID1364568Bactericidal activity against multidrug-resistant Acinetobacter baumannii ATCC BAA 18002 after 48 hrs by resazurin dye based broth microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID1701634Antibacterial activity against methicilin-resistant Staphylococcus aureus USA300 FPR3757 incubated for 20 hrs by microbroth dilution assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.
AID585164Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA G2576U mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400054Bactericidal activity against Klebsiella pneumoniae ATCC 12019 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID584972Antibacterial activity against wild type Mycobacterium smegmatis after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID744239Antibacterial activity against Escherichia coli at 320 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID585161Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA A2503G mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID509632Antimicrobial activity against Staphylococcus aureus 25 transformant carrying plasmid pKKS25 and expressing erm(T), dfrKtet(L), tet(K), tet(M), mecA and blaZ genes by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID1067011Antimicrobial activity against methicillin-resistant Staphylococcus aureus USA300 after 20 hrs by two-fold broth dilution assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID744240Antibacterial activity against methicillin-resistant Staphylococcus epidermidis at 80 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID1364571Growth inhibition of multidrug-resistant Acinetobacter baumannii ATCC BAA 18002 after 48 hrs by resazurin dye based broth microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID1154693Oral bioavailability in duck2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID1400062Bactericidal activity against Bacillus subtilis ATCC 6051 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1428686Antibacterial activity against Enterococcus faecium ATCC 35667 after overnight incubation by broth dilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127Design, synthesis and antibacterial evaluation of novel pleuromutilin derivatives possessing piperazine linker.
AID1400034Bactericidal activity against replicating Mycobacterium tuberculosis H37Rv incubated for 15 days under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400043Bactericidal activity against Staphylococcus aureus BAA 1683 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID585167Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA G2032A, C2499A mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400023Antibacterial activity against replicating Mycobacterium tuberculosis H37Rv incubated for 15 days under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400060Bactericidal activity against Streptococcus salivarius ATCC 6301 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1067016Binding affinity to Escherichia coli MRE600 23S rRNA assessed as protection of U2585 at 5 uM by footprinting assay relative to control in presence of CMCT2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID1400056Bactericidal activity against Acinetobacter baumannii ATCC 19606 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400019Antibacterial activity against Staphylococcus aureus incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400055Antibacterial activity against Acinetobacter baumannii ATCC 19606 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID744238Antibacterial activity against Escherichia coli at 160 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID585162Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA G2505A mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400053Antibacterial activity against Klebsiella pneumoniae ATCC 12019 incubated for 24 hrs under aerobic condition by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID744237Antibacterial activity against Streptococcus agalactiae at 320 ug/ml after 24 hrs by Oxford cup assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and antibacterial evaluation of novel pleuromutilin derivatives.
AID684093Binding affinity to Escherichia coli 23S rRNA U2506 assessed as degree of protection against CMCT at 5 uM by Chemical footprinting analysis relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
A click chemistry approach to pleuromutilin derivatives, part 2: conjugates with acyclic nucleosides and their ribosomal binding and antibacterial activity.
AID585163Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA C2571G mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID585173Antibacterial activity against Mycobacterium smegmatis harboring 23S rRNA C2055A, A2572U mutant after 24 generation times2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.
AID1400028Inhibition of protein translation/transcription in Escherichia coli S30 cell extract at 0.1 ug/ml using circular DNA with pBESTluc after 60 mins by luciferase reporter gene assay2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1638643Antimicrobial activity against Wolbachia pipientis infected in Asian tiger mosquito C6/36 cells after 7 days by SYTO11 DNA dye-based confocal imaging analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.
AID1400027Selectivity index, ratio of IC50 for African green monkey Vero cells to MIC100 for replicating Mycobacterium tuberculosis H37Rv by MABA2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1428685Antibacterial activity against Enterococcus faecalis ATCC 29212 after overnight incubation by broth dilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127Design, synthesis and antibacterial evaluation of novel pleuromutilin derivatives possessing piperazine linker.
AID1067010Antimicrobial activity against methicillin-resistant Staphylococcus aureus RN4220 after 20 hrs by two-fold broth dilution assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A click chemistry approach to pleuromutilin derivatives. Part 3: extended footprinting analysis and excellent MRSA inhibition for a derivative with an adenine phenyl side chain.
AID1867950Antibacterial activity against Shigella dysenteriae assessed as inhibition of bacterial growth2022European journal of medicinal chemistry, Jul-05, Volume: 237Design, synthesis and antibacterial activity of novel pleuromutilin derivatives with thieno[2,3-d]pyrimidine substitution.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.37)18.2507
2000's15 (20.55)29.6817
2010's49 (67.12)24.3611
2020's8 (10.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.33 (24.57)
Research Supply Index4.14 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index43.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (8.77%)5.53%
Trials0 (0.00%)5.53%
Reviews6 (10.53%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other46 (80.70%)84.16%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ammonium hydroxide
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.		2.0610azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		7.1310elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		2.0610alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		2.1710phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.1710phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.4111monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		3.2310L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
ethyl acetate
ethyl acetate : The acetate ester formed between acetic acid and ethanol.		2.0610acetate ester;
ethyl ester;
volatile organic compound		EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor;
metabolite;
polar aprotic solvent;
Saccharomyces cerevisiae metabolite
pyrimidine
pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.		2.2110diazine;
pyrimidines		Daphnia magna metabolite
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.0610benzenes;
phenyl acetates
fluvalinate
fluvalinate: RN given refers to 2-cyano isomer (DL)-isomer		3.2310(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide		agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide
enrofloxacin
Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.		3.4111cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
danofloxacin
[no description available]		2.5920quinolines
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		2.1710carbamate ester;
oxazolidinone		metabolite
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.1710macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
linezolid
[no description available]		2.1710acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.1710macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
u 100480
U 100480: structure given in first source		2.1710
tiamulin
tiamulin: 81723 HFU and tiamutin are for fumarate salt; prevents senescence in ascomycete; pleuromutilin derivative; RN given refers to ((3aS-(3aalpha,4beta,5alpha,6alpha,8beta,9alpha,9abeta,10S*))-isomer. tiamulin : A carbotricyclic compound that is pleuromutilin in which the hydroxyacetate group is replaced by a 2-{[2-(diethylamino)ethyl]sulfanyl}acetate group. An antibacterial drug, tiamulin is used in veterinary medicine (generally as its hydrogen fumarate salt) for the treatment of swine dysentery caused by Serpulina hyodysenteriae.		6.4160carbotricyclic compound;
carboxylic ester;
cyclic ketone;
organic sulfide;
secondary alcohol;
semisynthetic derivative;
tertiary amino compound;
tetracyclic diterpenoid		antibacterial drug
lincomycin
Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.		8.8221carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0510prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
fumarates
Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)		2.1310butenedioate;
C4-dicarboxylate		human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite
tylvalosin
3-acetyl-4''-isovaleryltylosin: structure given in first source		7.520
retapamulin
retapamulin: a synthetic pleuromutilin		4.9540carbotricyclic compound;
carboxylic ester;
cyclic ketone
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.0510aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
sepharose
agarose : A linear polysaccharide made up from alternating D-galactose and 3,6-anhydro-alpha-L-galactopyranose residues joined by alpha-(1->3)- and beta-(1->4)-linkages.		2.110
bc-3781
[no description available]		3.1810
tilmicosin
tilmicosin: semi-synthetic antibiotic. tilmicosin : A macrolide antibiotic with formula C46H80N2O13. It is used for the treatment of respiratory disease in cattle at high risk of developing bovine respiratory disease associated with Mannheimia haemolytica.		7.1510
tylosin
[no description available]		7.8230
chlortetracycline
Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.		210
pyrethrins
[no description available]		3.2310
agar
Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.		2.1310
mutilin
mutilin: structure in first source		3.1410
pk 11195
PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine		2.6320aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent
jtv519
[no description available]		2.6320
alprazolam
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.		2.6320organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
dan 2163
[no description available]		2.6320aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amlexanox
amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.		2.6320monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
astemizole
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.		2.6320benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
benzbromarone
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.		2.63201-benzofurans;
aromatic ketone		uricosuric drug
bisindolylmaleimide i
bisindolylmaleimide I: a bis(indolyl)maleimide		2.6320
bufexamac
Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.		2.6320aromatic ether;
hydroxamic acid		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cadralazine
cadralazine: structure given in first source		2.6320organic molecular entity
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.1710aromatic ether;
nitrile;
polyether;
tertiary amino compound
carvedilol
[no description available]		2.6320carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
cetirizine
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.		2.6320ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
chlorcyclizine
chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness		2.6320diarylmethane
ci 994
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.		2.6320acetamides;
benzamides;
substituted aniline		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
cyclosporine
cyclosporin A : A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.		2.2510
fenbendazole
Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.		2.6320aryl sulfide;
benzimidazoles;
carbamate ester		antinematodal drug
go 6976
[no description available]		2.6320indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		2.6320aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
homochlorocyclizine
homochlorocyclizine: RN given refers to parent cpd		2.6320diarylmethane
hydroxyzine
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.		2.6320hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
ifenprodil
ifenprodil: NMDA receptor antagonist		2.6320piperidines
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.1710carbohydrazideantitubercular agent;
drug allergen
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone
ZM39923: structure in first source		2.6320naphthalenes
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		2.6320cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		2.6320benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		2.6320aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
mephenesin
Mephenesin: A centrally acting muscle relaxant with a short duration of action.. 1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.		2.6320aromatic ether;
glycerol ether
niclosamide
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.		2.6320benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
oxibendazole
oxibendazole: structure		2.6320benzimidazoles;
carbamate ester
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine
4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine: a 5-HT(1A) ligand; structure in first source		2.6320
perphenazine
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.		2.6320N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
pimobendan
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source		2.6320benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
ag 1879
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor		2.6320aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one
[no description available]		2.2510indoles
ro 31-8220
Ro 31-8220: a protein kinase C inhibitor		2.6320imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
ropinirole
[no description available]		2.6320indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		2.6320dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
[no description available]		2.2510stilbenoid
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.4620aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.		2.6320aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
zotepine
zotepine: structure		2.6320dibenzothiepine;
tertiary amino compound		alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		2.0510penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.4620C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.0510kanamycinsbacterial metabolite
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.6320alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
oxacillin
Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.		2.0510penicillinantibacterial agent;
antibacterial drug
benziodarone
benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)		2.6320aromatic ketone
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.0510beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
cyclizine
Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.		2.2110N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
trehalose
alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.		2.6320trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
triclocarban
triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure. triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively.		2.6320dichlorobenzene;
monochlorobenzenes;
phenylureas		antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic
framycetin
Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.		2.0510aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
4-tert-octylphenol
4-tert-octylphenol: structure given in first source		2.6320alkylbenzene
ethamivan
ethamivan: minor descriptor (65-72); major descriptor (73-86); on-line search BENZAMIDES (66-86); INDEX MEDICUS search BENZAMIDES (65-72); ETHAMIVAN (73-86). etamivan : Phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse.		2.6320methoxybenzenes;
phenols
methysergide
Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.		2.6320ergoline alkaloid
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		2.6320isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.6320furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		2.4620cyclic ketone;
erythromycin
etonitazene
etonitazene: was heading 1979-94 (see under BENZIMIDAZOLES 1979-90); ETONITAZIN was see ETONITAZENE 1979-94; use BENZIMIDAZOLES to search ETONITAZENE 1979-94; narcotic analgesic similar to morphine in action; used mainly to study narcotic habituation, tolerance, and withdrawal in laboratory animals		2.6320
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		2.1710ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.0510glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		2.0510cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
clothiapine
clothiapine: was heading 1975-94 (was see under DIBENZOTHIAZEPINES 1975-90); CLOTIAPINE was see CLOTHIAPINE 1978-94; use DIBENZOTHIAZEPINES to search CLOTHIAPINE 1975-94; antipsychotic similar to clozapine		2.6320dibenzothiazepine
benperidol
Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)		2.6320aromatic ketone
7-hydroxychlorpromazine
7-hydroxychlorpromazine: RN given refers to parent cpd		2.6320phenothiazines
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.6320delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
thenalidine
thenalidine: antihistaminic, antipruritic; RN in Chemline for thenalidine calcium: 67250-62-8; structure		2.6320dialkylarylamine;
tertiary amino compound
bromocriptine
Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.		2.6320indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
dexchlorpheniramine
dexchlorpheniramine: RN given refers to parent cpd(S)-isomer		2.6320chlorphenamine
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		2.0710penicillin allergen;
penicillin		antibacterial drug
dv 1006
[no description available]		2.6320
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		2.1510amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
climbazole
1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one : A ketone that is butan-2-one substituted by a 4-chlorophenoxy and a 1H-imidazol-1-yl group at position 1 and 2 methyl groups at position 3.		2.6320aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes
triadimenol
triadimenol : A member of the class of triazoles that is 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butane-1,2-diol substituted at position O1 by a 4-chlorophenyl group. A fungicide for cereals, beet and brassicas used to control a range of diseases including powdery mildew, rusts, bunts and smuts.		2.6320aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite
amonafide
xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor		2.6320isoquinolines
flupirtine
flupirtine: RN given refers to parent cpd without isomeric designation		2.6320aminopyridine
chaetochromin
chaetochromin: from Chaetomium spp.; RN given refers to chaetochromin A		2.6320
enoximone
Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.		2.6320aromatic ketone
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		2.6320aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
aloxistatin
aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.		2.2110epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide		anticoronaviral agent;
cathepsin B inhibitor
indocate
[no description available]		2.6320
N(4)-acetylsulfathiazole
N(4)-acetylsulfathiazole : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a 1,3-thiazol-2-yl group at the nitrogen atom. It is a metabolite of sulfathiazole.		2.63201,3-thiazoles;
acetamides;
sulfonamide		marine xenobiotic metabolite
cyclizine hydrochloride
[no description available]		2.2510
2,3-trimethylene-4-quinazolone
2,3-trimethylene-4-quinazolone: structure in first source		2.6320quinazolines
talinolol
[no description available]		2.1710ureas
1,3-dimethyluric acid
1,3-dimethyluric acid : An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trionesubstituted by methyl groups at N-1 and N-3.		2.6320oxopurinemetabolite
enrofloxacin
Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.		2.0510cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
danofloxacin
[no description available]		2.6320quinolines
nitrefazole
[no description available]		2.6320imidazoles
methotrimeprazine
Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.		2.6320phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
honokiol
[no description available]		2.6320biphenyls
9-methoxyellipticine
9-methoxyellipticine: RN given refers to parent cpd		2.6320
3-aminophenoxazone
3-aminophenoxazone: also inhibits sulfatase; structure		2.6320phenoxazine
3-deazaneplanocin
3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist		2.6320
tryptanthrine
tryptanthrine: minor constituent of traditional Chinese medicine qing dai		2.6320alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound
2-chlorodiazepam
[no description available]		2.6320
Polycartine B
[no description available]		2.6320phenazines
aminoquinuride dihydrochloride
[no description available]		2.6320
thioproperazine mesylate
[no description available]		2.6320phenothiazines
n(6)-(delta(2)-isopentenyl)adenine
N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.		2.63206-isopentenylaminopurinecytokinin
4-methyl-N-(phenylmethyl)benzenesulfonamide
[no description available]		2.6320sulfonamide
zpck
ZPCK: alkylates histidine residue at active center of bovine chymotrypsin		2.6320
sr141716
[no description available]		2.6320amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
[no description available]		2.2510aromatic ketone
fingolimod
fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.		2.6320aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
tesmilifene
[no description available]		2.6320diarylmethane
sr 27897
SR 27897: structure given in first source; a CCK(A) receptor antagonist		2.6320indolyl carboxylic acid
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine
N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)		2.6320leucine derivative
norketamine
norketamine: metabolite of ketamine; RN given refers to cpd without isomeric designation		2.6320organochlorine compound
indatraline
indatraline: RN given for (trans)-isomer; structure in first source		2.6320indanes
methotrexate
[no description available]		2.6320dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
salvinorin a
salvinorin A: from the herb, Salvia divinorum		2.2110organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide
4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide: increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol		2.6320
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide
N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide: binds with high affinity to glial mitochondrial diazepam binding inhibitor receptors & increases mitochondrial steroidogenesis		2.6320phenylindole
l 741626
3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole: structure in first source		2.6320piperidines
dx 8951
[no description available]		2.6320pyranoindolizinoquinoline
pirlimycin
pirlimycin: RN given refers to (mono-HCl(2S-cis)-isomer)		2.0510
tipifarnib
[no description available]		2.6320imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		2.63202,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
avasimibe
[no description available]		2.6320monoterpenoid
l 163191
[no description available]		2.6320
dizocilpine
[no description available]		2.6320secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
s-benzylcysteine
[no description available]		2.6320S-aryl-L-cysteine zwitterion
chelidonine
chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)		2.6320alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
lapatinib
[no description available]		2.6320furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
roxindole
[no description available]		2.6320indolesalpha-adrenergic antagonist;
serotonergic drug
conidendrin
[no description available]		2.6320
Porfiromycine
[no description available]		2.6320mitomycin
nsc 95397
[no description available]		2.63201,4-naphthoquinones
4-methyl-2-quinazolinamine
4-methyl-2-quinazolinamine: from Streptomyces of TCM plant; structure in first source		2.6320
2-glycineamide-5-chlorophenyl-2-pyrryl ketone
[no description available]		2.6320
niguldipine hydrochloride
[no description available]		2.6320
2,5-bis(5-hydroxymethyl-2-thienyl)furan
[no description available]		2.6320thiophenes
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.63201,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
bardoxolone methyl
methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source		2.2110cyclohexenones
Destruxin B
[no description available]		2.6320cyclodepsipeptide
tosylphenylalanyl chloromethyl ketone
Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.		2.6320alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
linezolid
[no description available]		2.7730acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		2.2110antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		2.7430
sitafloxacin
[no description available]		2.2110fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
2'-c-methylcytidine
2'-C-methylcytidine: structure in first source		2.6320
jp-1302
[no description available]		2.6320
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one
[no description available]		2.6320benzodiazepine
tenatoprazole
Tenatoprazole: structure in first source		2.6320imidazopyridine
s 1033
[no description available]		2.6320(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
5-[(2-fluoroanilino)methyl]-8-quinolinol
[no description available]		2.6320hydroxyquinoline
benidipine hydrochloride
[no description available]		2.2510
benidipine
benidipine: RN refers to (R*,R*)-(+-)-isomer		2.2110
tiamulin
tiamulin: 81723 HFU and tiamutin are for fumarate salt; prevents senescence in ascomycete; pleuromutilin derivative; RN given refers to ((3aS-(3aalpha,4beta,5alpha,6alpha,8beta,9alpha,9abeta,10S*))-isomer. tiamulin : A carbotricyclic compound that is pleuromutilin in which the hydroxyacetate group is replaced by a 2-{[2-(diethylamino)ethyl]sulfanyl}acetate group. An antibacterial drug, tiamulin is used in veterinary medicine (generally as its hydrogen fumarate salt) for the treatment of swine dysentery caused by Serpulina hyodysenteriae.		3.4970carbotricyclic compound;
carboxylic ester;
cyclic ketone;
organic sulfide;
secondary alcohol;
semisynthetic derivative;
tertiary amino compound;
tetracyclic diterpenoid		antibacterial drug
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one
[no description available]		2.6320quinazolines
chlorprothixene
(E)-chlorprothixene : A chlorprothixene in which the double bond adopts an (E)-configuration.		2.6320chlorprothixene
jrf 12
N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor		2.6320
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester
[no description available]		2.6320methoxybenzenes;
substituted aniline
3-hydroxypyridine, sodium salt
[no description available]		2.6320
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide
[no description available]		2.6320naphthalenecarboxamide
5-[(2-bromoanilino)methyl]-8-quinolinol
[no description available]		2.6320hydroxyquinoline
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide
3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide: structure in first source		2.6320
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline
[no description available]		2.6320aromatic amine
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide
[no description available]		2.6320piperidinecarboxamide
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol
[no description available]		2.6320hydroxyquinoline
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide
[no description available]		2.6320acetamides;
anilide
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide
[no description available]		2.6320aromatic amide;
thiophenes
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone
[no description available]		2.6320dimethoxybenzene
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide
[no description available]		2.6320aromatic amide
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide
[no description available]		2.6320aromatic ether
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione
[no description available]		2.6320maleimides
Src Inhibitor-1
Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.		2.6320aromatic ether;
polyether;
quinazolines;
secondary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one
[no description available]		2.6320dimethoxybenzene
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide
[no description available]		2.6320quinolines
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
[no description available]		2.6320pyrroles
bi-78d3
[no description available]		2.6320aryl sulfide
kartogenin
kartogenin: promotes chondrocyte differentiation; structure in first source		2.6320
lincomycin
Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.		2.0510carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
ranitidine
Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.		2.1710C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
toremifene
Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.		2.2110aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
vx-745
[no description available]		2.6320aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		2.63201,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
zd 6474
CH 331: structure in first source		2.6320aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
[no description available]		2.6320indoles
nih-12848
NIH-12848: inhibits phosphatidylinositol 5-phosphate 4-kinase gamma; structure in first source		2.6320
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide
[no description available]		2.6320quinazolines
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone
[no description available]		2.6320benzimidazoles
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile
[no description available]		2.6320imidazopyridine
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
[no description available]		2.6320aromatic ketone
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester
[no description available]		2.6320oxopurine
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester
[no description available]		2.6320organonitrogen compound;
organosulfur compound
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide
[no description available]		2.6320quinolines
LSM-1924
[no description available]		2.6320organic heterotricyclic compound;
organooxygen compound
ferrostatin-1
ferrostatin-1: inhibits ferroptosis, an iron-dependent form of nonapoptotic cell death; structure in first source. ferrostatin-1 : An ethyl ester resulting from the formal condensation of the carboxy group of 3-amino-4-(cyclohexylamino)benzoic acid with ethanol. It is a potent inhibitor of ferroptosis, a distinct non-apoptotic form of cell death caused by lipid peroxidation. It is also a radical-trapping antioxidant and has the ability to reduce the accumulation of lipid peroxides and chain-carrying peroxyl radicals.		2.6320ethyl ester;
primary arylamine;
substituted aniline		antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine
[no description available]		2.6320C-nitro compound
rabeprazole(1-)
[no description available]		2.6320organic nitrogen anion
ncgc00099374
[no description available]		2.6320
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide
[no description available]		2.6320benzamides
luteolin
[no description available]		2.63203'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
cyclosporine
[no description available]		2.2110
kaempferol
[no description available]		2.63207-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
genistein
[no description available]		2.63207-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
mycophenolate mofetil
mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.		2.6320carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
bruceantin
[no description available]		2.6320triterpenoid
chrysin
chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.		2.63207-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
daidzein
[no description available]		2.63207-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
neticonazole
neticonazole: RN refers to (E)-isomer. neticonazole : An enamine that is ethene which is substituted at positions 1, 1, and 2 by o-pentoxyphenyl, 1H-imidazol-1-yl, and methylthio groups, respectively (the E isomer). An inhibitor of P450-dependent C-14alpha-demethylation of lanosterol (preventing conversion to ergosterol and inhibiting cell wall synthesis in fungi), it is used in Japan (generally as the corresponding hydrochloride salt) as an antifungal drug for the treatment of superficial skin infections.		2.6320aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide		antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine
synaptamide: structurally similar to the endocannabinoid N-arachidonoylethanolamine (anandamide). N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine : An N-acylethanolamine 22:6 that is the ethanolamide of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid.		2.6320endocannabinoid;
N-acylethanolamine 22:6
n-oleoylethanolamine
N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.		2.6320endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1		EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
alpha-zearalenol
[no description available]		2.6320macrolide
su 9516
[no description available]		2.6320
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
[no description available]		2.6320triazolopyrimidines
sb 277011
SB 277011: structure in first source		2.6320
sb 223412
SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source		2.6320
sr 59230a
[no description available]		2.6320tetralins
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide
[no description available]		2.6320pyrimidines
kn 62
KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II		2.6320piperazines
MeJA
[no description available]		2.6320Jasmonate derivatives
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-
1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-: structure in first source		2.6320
pd 161570
PD 161570: structure in first source		2.6320
palbociclib
[no description available]		2.6320aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621
[no description available]		2.6320sulfonamide
virginiamycin factor s1
virginiamycin factor S1: a component of VIRGINIAMYCIN; was EP to VIRGINIAMYCIN 1992-2001. virginiamycin S1 : A cyclodepsipeptide that is N-(3-hydroxypicolinoyl)-L-threonyl-D-alpha-aminobutyryl-L-prolyl-N-methyl-L-phenylalanyl-4-oxo-L-pipecoloyl-L-2-phenylglycine in which the carboxy group of the 2-phenylglycine moiety has undergone formal intramolecular condensation with the hydroxy group of the N-(3-hydroxypicolinoyl)-L-threonyl to give the corresponding 19-membered ring lactone. It is one of the two major components of the antibacterial drug virginiamycin, produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others.		2.6320cyclodepsipeptide;
macrolide antibiotic		antibacterial drug;
bacterial metabolite
streptogramin a
Streptogramin A: A specific streptogramin group A antibiotic produced by Streptomyces graminofaciens and other bacteria.		2.05101,3-oxazoles;
cyclic ketone;
enamide;
lactam;
macrolide antibiotic;
macrolide;
pyrroline;
secondary alcohol;
secondary carboxamide;
tertiary carboxamide		antibacterial drug;
Mycoplasma genitalium metabolite
fenoterol
fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.		2.6320hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
xib 4035
XIB 4035: a GFRalpha-1 agonist; structure in first source		2.6320
gw-5074
[no description available]		2.2110
belotecan
belotecan: structure in first source		2.6320pyranoindolizinoquinoline
norgestimate
[no description available]		2.6320ketoxime;
steroid ester;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
b 43
RK-24466 : A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively).		2.6320aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine
[no description available]		2.6320
methiazole
methiazole: a parasitostatic agent		2.6320benzimidazoles;
carbamate ester
sb 218795
SB 218795: structure in first source		2.6320quinolines
bvt.948
[no description available]		2.6320
fk 866
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source		2.2110benzamides;
N-acylpiperidine
a 38503
[no description available]		2.6320
retapamulin
retapamulin: a synthetic pleuromutilin		3.2750carbotricyclic compound;
carboxylic ester;
cyclic ketone
parthenolide
[no description available]		2.2110sesquiterpene lactonedrug allergen;
inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
krn 633
N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source		2.6320
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid
[no description available]		2.6320organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
gw 501516
GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.		2.63201,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
dolastatin 10
dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.		2.63201,3-thiazoles;
tetrapeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent
spc-839
SPC-839: an inhibitor of activator protein 1; structure in first source		2.6320
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		2.6320benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
nu 7026
2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source		2.6320organic heterotricyclic compound;
organooxygen compound
osi 930
OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source		2.6320aromatic amide
ticagrelor
Ticagrelor: An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.. ticagrelor : A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome.		2.6320aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor
l 692585
[no description available]		2.6320peptide
pi103
PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce		2.6320aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
pleuromutilin
[no description available]		2.5820
nnc 26-9100
NNC 26-9100: structure in first source		2.6320aminopyridine
gentamicin sulfate
[no description available]		2.0510
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine
[no description available]		2.6320
tivozanib
N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source		2.6320aromatic ether
hki 272
[no description available]		2.2110nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide
[no description available]		2.6320
tae226
TAE226: an adhesion kinase inhibitor, offers an attractive therapeutic approach in ovarian carcinoma; structure in first source		2.6320morpholines
gw0742
GW 610742: structure in first source		2.6320monocarboxylic acid
u 18666a
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.		2.6320hydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor
sb 525334
6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor		2.6320quinoxaline derivative
bx795
BX795: structure in first source		2.6320ureas
azd 6244
AZD 6244: a MEK inhibitor		2.6320benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source		2.6320
bay 61-3606
[no description available]		2.6320pyrimidines
sd-208
[no description available]		2.6320
crenolanib
[no description available]		2.6320aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cj 033466
CJ 033466: structure in first source		2.6320
cc 401
CC 401: an anthrapyrazolone		2.6320pyrazoles;
ring assembly
PB28
PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.		2.6320aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
arterolane
arterolane: a trioxolane with antimalarial activity; structure in first source. arterolane : An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.		2.6320
cariprazine
cariprazine: Structure in first source. cariprazine : An N-alkylpiperazine that is N,N-dimethyl-N'-{trans-4-[2-(piperazin-1-yl)ethyl]cyclohexyl}urea substituted at position 4 on the piperazine ring by a 2,3-dichlorophenyl group. Used (as the hydrochloride salt) for treatment of schizophrenia and bipolar disorder.		2.6320
krp-203
[no description available]		2.6320
regorafenib
[no description available]		2.6320(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
at 7867
[no description available]		2.6320monochlorobenzenes;
piperidines;
pyrazoles		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester
[no description available]		2.6320pyrroloquinoline
ptc 124
[no description available]		2.6320oxadiazole;
ring assembly
degrasyn
degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source		2.6320
bi 2536
[no description available]		2.6320
azd 1152
AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.		2.6320anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor;
prodrug
carfilzomib
[no description available]		2.6320epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
idelalisib
idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.		2.6320aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
motesanib
[no description available]		2.6320pyridinecarboxamide
pf-562,271
[no description available]		2.6320indoles
gliocladin c
gliocladin C: structure in first source		2.6320
sb 706504
[no description available]		2.6320
ku-0060648
[no description available]		2.6320dibenzothiophenes
bgt226
BGT226 free base : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor.. BGT226 : The maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor.		2.6320aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
n-desmethyldanofloxacin
N-desmethyldanofloxacin: structure given in first source		2.6320
azd 1152-hqpa
AZD2811: has antineoplastic activity; structure in first source		2.6320anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor
CDN1163
CDN1163: a SERCA2 activator with antidiabetic activity; structure in first source. CDN1163 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-isopropoxybenzoic acid with the primary amino group of 2-methylquinolin-8-amine. An allosteric activator of sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA).		2.6320aromatic ether;
quinolines;
secondary carboxamide		SERCA activator
azamulin
azamulin: a Cyp3A inhibitor; structure in first source		2.110
gsk 269962a
[no description available]		2.6320
pha 848125
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor		2.6320
nvp-bhg712
[no description available]		2.6320benzamides
pf 04217903
[no description available]		2.6320quinolines
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one
[no description available]		2.6320aromatic ketone
ph 797804
PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.		2.6320aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone		anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
srt1720
[no description available]		2.6320
purfalcamine
purfalcamine: a PfCDPK-1 inhibitor; structure in first source		2.6320
bms 754807
BMS 754807: an IGR-1R kinase inhibitor; structure in first source		2.6320pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ponatinib
[no description available]		2.6320(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor
quizartinib
[no description available]		2.6320benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
PP121
[no description available]		2.6320aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor
navitoclax
[no description available]		2.6320aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
gsk 650394
[no description available]		2.6320phenylpyridine
dcc-2036
rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent		2.6320organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines		tyrosine kinase inhibitor
cabozantinib
cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.		2.6320aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
TAK-580
MLN 2480: brain-penetrant RAF dimer antagonist. TAK-580 : A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults.		2.63201,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one
[no description available]		2.6320chromones
bc-3781
[no description available]		2.2110
pf 3758309
PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source		2.6320organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source		2.6320benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		2.6320aryl sulfide;
thienopyrimidine
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		2.6320aryl sulfide;
thienopyrimidine
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		2.6320aryl sulfide;
thienopyrimidine
baricitinib
[no description available]		2.6320azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine
[no description available]		2.6320quinazolines
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
ML-265: a small molecule activator of PKM2		2.6320organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide
[no description available]		2.6320hydroxyquinoline
p505-15
[no description available]		2.6320
mrt67307
MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source		2.6320aromatic amine
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide
[no description available]		2.6320piperazines
ribociclib
ribociclib: inhibits both CDK4 and CDK6		2.6320
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone
[no description available]		2.6320aromatic ketone;
thienopyrimidine
pha 793887
[no description available]		2.6320piperidinecarboxamide
gsk 2334470
GSK 2334470: a PDK1 inhibitor; structure in first source		2.2110indazoles
ml228 probe
ML228 probe: structure in first source. ML228 : A member of the class of 1,2,4-triazines in which the triazine ring is substituted at positions 3, 5, and 6 by pyridin-2-yl, ([biphenyl]-4-ylmethyl)amin, and methyl groups, respectively. It is an activator of the hypoxia inducible factor (HIF) pathway.		2.63201,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound		hypoxia-inducible factor pathway activator
pf-03882845
[no description available]		2.6320
jq1 compound
[no description available]		2.6320carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
pf-04620110
PF-04620110: a DGAT1 inhibitor; structure in first source		2.6320
gsk525762a
molibresib: mimicks acetylated histones; structure in first source		2.6320benzodiazepine
birinapant
birinapant: a Smac mimetic with antineoplastic activity		2.2110dipeptide
torin 1
torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		2.6320N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines		antineoplastic agent;
mTOR inhibitor
abt-199
venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.		2.6320aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea
[no description available]		2.6320ureas
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide
[no description available]		2.6320(trifluoromethyl)benzenes
ncgc00242364
NCGC00242364: structure in first source		2.6320quinazolines
gsk1210151a
GSK1210151A: inhibitor of the BET family of proteins; structure in first source		2.6320imidazoquinoline
hs-173
[no description available]		2.6320
sr1664
[no description available]		2.6320indolecarboxamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide: inhibits phosphopantetheinyl transferase; structure in first source		2.6320
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide
[no description available]		2.2510benzamides;
N-acylpiperidine
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.2510aminoquinoline
cudc-907
[no description available]		2.6320
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.4620
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		2.2110
methacycline
Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.		2.2110
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.1710benzenes;
hydroxycoumarin;
methyl ketone
methacycline monohydrochloride
[no description available]		2.2510
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid
[no description available]		2.6320quinolines
agi-5198
AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source		2.6320
cep-32496
agerafenib: inhibitor of RAF family kinases; structure in first source		2.6320
epz004777
[no description available]		2.6320N-glycosyl compound
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid
[no description available]		2.6320organonitrogen heterocyclic compound
entecavir
[no description available]		2.6320benzamides;
N-acylpiperidine
gkt137831
setanaxib: NOX4/NOX1 inhibitor; a pyrazolopyridine dione derivative		2.6320
vx-509
[no description available]		2.6320
vx-970
berzosertib: an ATR kinase inhibitor		2.6320sulfonamide
gs-9973
[no description available]		2.6320
amg 925
AMG-925 : An organic heterotricyclic compound that is 9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine which is substituted by a [6-(hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]nitrilo group at position 2 and by a trans-4-methylcyclohexyl group at position 9. It is a FLT3 and CDK4 dual kinase inhibitor that has antineoplastic activity. Currently under clinical investigation in patients with relapsed or refractory acute myeloid leukemia (AML).		2.6320
gne-618
GNE-618: inhibits nicotinamide phosphoribosyl transferase; structure in first source		2.6320
g007-lk
G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source		2.6320
volitinib
[no description available]		2.6320
ML355
ML355: 12-Lipoxygenase inhibitor. ML355 : A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis.		2.6320benzothiazoles;
monomethoxybenzene;
phenols;
secondary amino compound;
substituted aniline;
sulfonamide		EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
platelet aggregation inhibitor
acp-196
acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.		2.6320aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk343
GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).		2.6320aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
agi-6780
AGI-6780: inhibits isocitrate dehydrogenases 1 and 2; structure in first source		2.6320
khs101
KHS101: a small molecule accelerates neuronal differentiation in the adult rat		2.6320
cb-839
[no description available]		2.6320
gsk-j4
GSK-J4: a JMJD3 inhibitor; structure in first source		2.6320organonitrogen heterocyclic compound
pf-06424439
PF-06424439: an inhibitor of diacylglycerol acyltransferase 2; structure in first source		2.6320
etp-46464
ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source		2.6320
onc201
TIC10 compound: a TRAIL-dependent antitumor agent; structure in first source		2.6320
kai407
KAI407: an antimalarial; structure in first source		2.6320
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source		2.6320
enasidenib
[no description available]		2.63201,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
oicr-9429
OICR-9429: antineoplastic; structure in first source		2.6320
lly-507
LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.		2.6320
at 9283
[no description available]		2.6320
hypoxanthine
[no description available]		2.6320nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.1710cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		2.6320benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
1-hydroxyphenazine
1-hydroxyphenazine: a virulence factor of Pseudomonas aeruginosa. 1-hydroxyphenazine : A phenazine carrying a hydroxy substituent at the 1-position.		2.6320phenazines
ro 24-7429
Ro 24-7429: blocks the action of the HIV tat protein; an analog of Ro 5-3335; Proc Natl Acad Sci U S A 1993 Jul 15;90(14):6395-9		2.6320benzodiazepine
nintedanib
nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.		2.6320
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide
[no description available]		2.6320catechols;
hydrazide;
hydrazone;
naphthols		EC 3.6.5.5 (dynamin GTPase) inhibitor
ver 52296
luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.		2.6320aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols		angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
rvx 208
apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation		2.6320
bmn 673
talazoparib: inhibits both PARP1 and PARP2; structure in first source		2.6320
ConditionIndicatedRelationship StrengthStudiesTrials
Pythiosis
A granulomatous disease caused by the aquatic organism PYTHIUM insidiosum and occurring primarily in horses, cattle, dogs, cats, fishes, and rarely in humans. It is classified into three forms: ocular, cutaneous, and arterial.		02.1710
Bacterial Disease
[description not available]		02.2110
Bacterial Infections
Infections by bacteria, general or unspecified.		02.2110
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.4811
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		03.4811
Co-infection
[description not available]		02.110
E coli Infections
[description not available]		02.5120
Eperythrozoonosis
[description not available]		05.6161
Poultry Diseases
Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.		04.2760
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.5120
Infections, Staphylococcal
[description not available]		02.7730
Swine Diseases
Diseases of domestic swine and of the wild boar of the genus Sus.		04.82120
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.7730
Dysentery
Acute inflammation of the intestine associated with infectious DIARRHEA of various etiologies, generally acquired by eating contaminated food containing TOXINS, BIOLOGICAL derived from BACTERIA or other microorganisms. Dysentery is characterized initially by watery FECES then by bloody mucoid stools. It is often associated with ABDOMINAL PAIN; FEVER; and DEHYDRATION.		07.9440
Bacterial Infections, Gram-Negative
[description not available]		02.5220
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		02.5220
Infections, Respiratory
[description not available]		02.1110
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		02.1110
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		02.1110
Intestinal Diseases
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.		03.511
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		02.1310
Clostridioides difficile Infection
[description not available]		02.1310
Clostridium Infections
Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.		02.1310
Lung Injury, Acute
[description not available]		02.0510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0510
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		07.0510
Infections, Spirochaetales
[description not available]		02.7130
Bovine Diseases
[description not available]		0533
Allergy, Drug
[description not available]		0210
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		0210
Infections, Pasteurella
[description not available]		03.821
Tuberculosis, Bovine
An infection of cattle caused by MYCOBACTERIUM BOVIS. It is transmissible to man and other animals.		03.3911
Foot Diseases
Anatomical and functional disorders affecting the foot.		03.3911
Gait Disorders, Animal
[description not available]		03.3911
Dermatitis
Any inflammation of the skin.		08.3911
Actinobacillus Infections
Infections with bacteria of the genus ACTINOBACILLUS.		0210
Weight Gain
Increase in BODY WEIGHT over existing weight.		0210
Acinetobacter Infections
Infections with bacteria of the genus ACINETOBACTER.		02.1510
Bancroftian Elephantiasis
[description not available]		02.2110
Elephantiasis, Filarial
Parasitic infestation of the human lymphatic system by WUCHERERIA BANCROFTI or BRUGIA MALAYI. It is also called lymphatic filariasis.		02.2110
Onchocerciasis
Infection with nematodes of the genus ONCHOCERCA. Characteristics include the presence of firm subcutaneous nodules filled with adult worms, PRURITUS, and ocular lesions.		02.2110